Annotation Detail
Information
- Associated Genes
- PIK3CA
- Associated Variants
-
PIK3CA p.Glu545Lys (p.E545K)
(
ENST00000263967.4,
ENST00000643187.1 )
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- 48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 2 out of the 39 patients had the E545K PIK3CA mutation in the absence of EGFR T790M, indicating that E545K may be an alternative mutation contributing to resistance.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1670
- Gene URL
- https://civic.genome.wustl.edu/links/genes/37
- Variant URL
- https://civic.genome.wustl.edu/links/variants/104
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Erlotinib,Afatinib,Gefitinib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 27304188